Venetoclax
Blasts 10 Percent or More of Bone Marrow Nucleated Cells
Aptose Biosciences Inc.Small moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the Blasts 10 Percent or More of Bone Marrow Nucleated Cells cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Sumithira Vasu | Phase 2 | BB |
Gilteritinib Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 3 | BB |
Cytosin-Arabinosid Sumithira Vasu | Phase 2 | BB |
Thiotepa Fred Hutchinson Cancer Center | Phase 2 | B |
Azacitidine Aptose Biosciences Inc. | Phase 2 | B |
View all 29 →
Same molecule, other indications
Venetoclax is also rated in:
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant
BBB
Indicative ·
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →